Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Combining Assets, Takeda/Millennium Outline Oncology Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.

You may also be interested in...



Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators

Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

Negative news increases pressure on Japanese pharma's oncology subsidiary Millennium Pharmaceuticals to perform.

Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later

Negative news increases pressure on Japanese pharma's oncology subsidiary Millennium Pharmaceuticals to perform.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel